FUJIFILM Pharmaceuticals USA
  • Home
  • Investigational Drug Development
  • Contract Services
    • LNPs and Liposomes
    • Nano-dispersion Technologies
  • Resources
    • Drug Delivery Formulation
    • Peer-Reviewed Publications and Conference Presentation
    • Oncology
    • Alzheimer’s Disease
  • News
  • About Us
  • Contact Us
Select Page

Fujifilm collaborates with Merck & Co., Inc., Kenilworth, N.J., U.S.A. in a clinical trial for advanced solid tumor in combination therapy of FF-10832, a liposome drug candidate with KEYTRUDA® (pembrolizumab)

FUJIFILM Corporation (President: Kenji Sukeno) announced that it will collaborate with Merck & Co., Inc., Kenilworth, N.J., U.S.A. (NYSE: MRK), known as MSD outside the United States and Canada. It signed a clinical collaboration agreement with MSD International GmbH, effective May 25, for the implementation of a clinical trial that evaluates a combination therapy with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, and Fujifilm’s drug candidate FF-10832, a liposome drug candidate. The liposome formulation is designed to utilize drug delivery system (DDS) technology to deliver drugs to affected sites.

Based on this agreement, Fujifilm plans to initiate a U.S. clinical trial in the fiscal year 2020 ending March 2021 to evaluate combination therapy using its FF-10832, a liposome formulation drug candidate, and KEYTRUDA® (pembrolizumab). The goal of the study will be to confirm the combination tolerability, pharmacokinetics and preliminary estimates of clinical activity of FF-10832 with Keytruda in selected tumor types.

A liposome formulation is a preparation that encapsulates active ingredients in liposomes, which are artificially constructed vesicles made from an organic substance such as phospholipids which make up cell and biological membranes. Liposomes are expected to deliver active ingredients efficiently to affected sites.

Fujifilm’s drug candidate, FF-10832, is a liposome formulation which encapsulates gemcitabine*1, an approved anti-cancer agent indicated for the treatment of a variety of solid tumors including pancreatic cancer. The clinical phase I study of FF-10832 targeting advanced solid tumors is currently underway in the U.S.  Preclinical studies in mice have demonstrated that a combination*2 of FF-10832 and immune checkpoint inhibitors increased CD8-positive cytotoxic T cells* 3, leading to longer survival compared to monotherapy.

Fujifilm will leverage its established proprietary technologies to tackle the development of new drugs responding to unmet medical needs, and also develop new DDS technologies, thereby creating new value and enhancing medical care worldwide.

*1: An anti-cancer agent developed by Eli Lilly and Company (generic name: gemcitabine; brand name: Gemzar). It is used as the first-line drug for pancreatic cancer, and is also being used for treating a wide range of other cancers such as lung and ovarian cancers.

*2: Combined administration of FF-10832 and anti-CTLA-4 antibody.  Anti CTLA-4 antibody and anti PD-1 antibody are immune checkpoint inhibitors which inhibit the mechanism that weakens the actions of immune cells (“immune checkpoint”) and activated immune cells attack cancer cells.

*3: A type of T-cell that makes immune responses. It recognizes cells that become a foreign body to the host, and destroys them.

For inquiries on information in this media release, please contact:
Media Contact: Corporate Communications Division    TEL: +81-3-6271-2000
Others: Pharmaceutical Products Division                     TEL: +81-3-6271-2171

 

###

PRIVACY POLICY      TERMS OF USE

TRUSTe
  • Follow
© 2022 FUJIFILM Pharmaceuticals U.S.A., Inc.
Cookies are important to the proper functioning of a site. To improve your experience, we use cookies to remember log-in details and provide secure log-in, collect statistics to optimize site functionality and deliver content tailored to your interest.
By continuing to use this site you are giving us your consent to do this. For more information you can read our Privacy Policy. Accept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT

Tumor targeting by liposomes

Liposomes provide a delivery system that carries the required amount of a drug to the specific area of the body. Because of that, one potential application for liposomes is anti-cancer formulations. Studies have suggested that liposomes are delivered to tumors through the enhanced permeability and retention (EPR) effect1. As a passive targeting mechanism, EPR effect allows the accumulation of drugs within the tumor tissue thanks to immature, highly permeable vasculature and ineffective lymphatic system that allow efficient extravasation of such macromolecules.

1 Yingchoncharoen P., Kalinowski D.S., Richardson D.R. 2016. Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come. Pharmacol Rev. 68(3):701-87.

Promising vehicle for nucleic acids

Nucleic acids (mRNA, siRNA, DNA aptamers, etc.) are the new frontiers of drug discovery. However, the industry has faced technological challenges in commercializing nucleic acid medicines due to their poor pharmacological stability. Lipid nanoparticle has been studied for a decade as a potential solution to this problem, which recently is coming to fruition in some clinical applications, such as mRNA-based COVID-19 vaccines.